Claims for Patent: 6,413,511

Summary for Patent: 6,413,511

Title:	Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
Abstract:	The subject invention concerns a method of introducing at least one DNA sequence expressing a protein or protein fragment which substantially alleviates articular cartilage defects. This method involves in vitro culture of chondrocytes, transfection of the chondrocytes with a recombinant vector housing the DNA sequence to be expressed, and delivery of the transfected chondrocytes to the damaged cartilage region. This method can also be used in tandem with synovial cell delivery techniques of the present invention. This method is also useful as a model in animal studies regarding joint pathologies.
Inventor(s):	Glorioso; Joseph C. (Cheswick, PA), Evans; Christopher H. (Pittsburgh, PA), Robbins; Paul D. (Pittsburgh, PA), Kane; Richard (Pittsburgh, PA)
Assignee:	University of Pittsburgh of the Commonwealth System of Higher Education (Pittsburgh, PA)
Application Number:	08/466,932
Patent Claims:	1. A method of producing a polypeptide within a mammalian chondrocyte, the method comprising generating a modified chondrocyte in vitro, said modified chondrocyte comprising a heterologous polynucleotide encoding said polypeptide, operably linked to a promoter, whereby said polypeptide is produced within said modified chondrocyte, and wherein introduction of the modified chondrocyte into a joint of a mammal and production of said polypeptide inhibits cartilage degradation or promotes cartilage growth. 2. The method of claim 1, wherein said mammal is a human. 3. The method of claim 1, wherein said joint is associated with a full-thickness articular cartilage defect. 4. The method of claim 1, wherein said joint is a knee joint. 5. The method of claim 1, wherein said heterologous polynucleotide is introduced into said chondrocyte using a viral vector. 6. The method of claim 5, wherein said viral vector is a retroviral vector. 7. The method of claim 6, wherein said retroviral vector is MFG. 8. The method of claim 5, wherein said viral vector is an adenoviral vector. 9. The method of claim 1, wherein said heterologous polynucleotide is introduced into said chondrocyte using a non-viral vector. 10. The method of claim 9, wherein said non-viral vector is introduced into said chondrocyte using a method selected from the group consisting of liposome-mediated transfection, calcium phosphate-mediated transfection, electroporation, and DEAE-dextran mediated transfection. 11. The method of claim 1, wherein said polypeptide is TGF-.beta.1. 12. The method of claim 1, wherein said polypeptide is IRAP. 13. The method of claim 1, wherein said chondrocyte is autologous. 14. The method of claim 1, wherein said chondrocyte is introduced into a cartilage articulation within said joint using a gel solution. 15. The method of claim 14, wherein said gel is introduced into said cartilage articulation using a fixative comprising fibrinogen and thrombin. 16. The method of claim 14, wherein said gel solution comprises collagen. 17. The method of claim 1, further comprising modifing a synovial cell, said modified synovial cell comprising a heterologous polynucleotide encoding a polypeptide of interest, operably linked to a promoter; whereby said polypeptide of interest is produced within said modified synovial cell within said joint. 18. The method of claim 17, wherein said modified synovial cell is introduced into said joint by intra-articular injection. 19. The method of claim 1, wherein said polypeptide that promotes cartilage growth is selected from the group consisting of TGF-.beta..sub.1, TGF-.beta..sub.2, TGF-.beta..sub.3, TGF-.alpha., IGF-1, FGF, and BMP. 20. The method of claim 1, wherein said polypeptide that causes cartilage degradation is selected from the group consisting of IL-1.alpha., IL-1.beta., TNF-.alpha., TNF-.beta., collagenase, stromelysin, and gelatinase. 21. A method of producing an non-human mammal model of arthritis, the method comprising generating a modified chondrocyte in vitro, said modified chondrocyte comprising a heterologous polynucleotide encoding a polypeptide, operably linked to a promoter, whereby said polypeptide is produced by said modified chondrocyte, and wherein introduction of the modified chondrocyte into a joint of a mammal and production of said polypeptide causes cartilage degradation. 22. The method of claim 1, wherein said polypeptide that inhibits cartilage degradation is selected from the group consisting of IRAP, soluble IL-1 receptor, soluble TNF-.alpha. receptor, TIMP-1, TIMP-2, TIMP-3, IL-4, IL10, vIL-10, and IL-13.

Details for Patent 6,413,511

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2019-07-02